Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Heat Biologics, KBI Biopharma Enter Development/Mfg. Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Heat Biologics, KBI Biopharma Enter Development/Mfg. Pact

KBI Biopharma to provide development and manufacturing services for cancer immunotherapies

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Heat Biologics, Inc., a biopharmaceutical company developing drugs designed to activate a patient’s immune system against cancer, and its subsidiary, Pelican Therapeutics, have entered a manufacturing agreement with KBI Biopharma to advance cancer-targeting immunotherapies. 
 
Last year, Pelican was awarded a $15.2 million grant from the Cancer Prevention and Research Institute of Texas to support manufacturing efforts, as well as to complete a 70-patient, Phase I trial. Under the agreement, KBI Biopharma will provide comprehensive development and manufacturing services in an effort to increase speed, productivity, stability and flexibility over traditional approaches to cell line development.

KBI is a biopharmaceutical CDMO that specializes in advanced biophysical and analytical protein characterization techniques towards the development of robust and scalable processes. KBI operates four facilities in Durham and Research Triangle Park, NC, Boulder, CO, and The Woodlands, TX.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics